ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΊΠΈΠ½Π΅ΡΠΈΠΊΠΈ ΡΠ°ΡΡΠ²ΠΎΡΠ΅Π½ΠΈΡ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ²
ΠΡΠ½ΠΎΠ²Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ°Π±ΠΎΡΡ Π΄ΠΎΠ»ΠΎΠΆΠ΅Π½Ρ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½Ρ Π½Π° ΠΌΠ΅ΠΆΠ²ΡΠ·ΠΎΠ²ΡΠΊΠΎΠΉ Π½Π°ΡΡΠ½ΠΎΠΉ ΠΊΠΎΠ½ΡΠ΅ΡΠ΅Π½ΡΠΈΠΈ ΡΡΡΠ΄Π΅Π½ΡΠΎΠ² ΠΈ ΠΌΠΎΠ»ΠΎΠ΄ΡΡ ΡΡΠ΅Π½ΡΡ «Π€Π°ΡΠΌΠ°ΡΠΈΡ Π² XXI Π²Π΅ΠΊΠ΅: ΡΡΡΠ°ΡΠ΅ΡΠ° ΠΏΠΎΠΊΠΎΠ»Π΅Π½ΠΈΠΉ» (Π‘Π°Π½ΠΊΡ-ΠΠ΅ΡΠ΅ΡΠ±ΡΡΠ³, 2009 Π³.), ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΠΎΠΉ Π½Π°ΡΡΠ½ΠΎ-ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠΎΠ½ΡΠ΅ΡΠ΅Π½ΡΠΈΠΈ «Π€Π°ΡΠΌΠ°ΡΠΈΡ ΠΠ°Π·Π°Ρ ΡΡΠ°Π½Π°: ΠΈΠ½ΡΠ΅Π³ΡΠ°ΡΠΈΡ Π½Π°ΡΠΊΠΈ, ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π°» (Π¨ΡΠΊΠΌΠ΅Π½Ρ, 2009 Π³.), Π½Π°ΡΡΠ½ΠΎ-ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠΎΠ½ΡΠ΅ΡΠ΅Π½ΡΠΈΠΈ Ρ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΠΌ ΡΡΠ°ΡΡΠΈΠ΅ΠΌ «ΠΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- Π‘ΠΠΠ‘ΠΠ Π‘ΠΠΠ ΠΠ©ΠΠΠΠ
- ΠΠΠΠΠ 1. ΠΠΠΠΠ ΠΠΠ’ΠΠ ΠΠ’Π£Π Π«
- 1. 1. ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² in vitro Π΄Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΈΠ½Π΅ΡΠΈΠΊΠΈ Π²ΡΡΠ²ΠΎΠ±ΠΎΠΆΠ΄Π΅Π½ΠΈΡ Π² Π°Π½Π°Π»ΠΈΠ·Π΅ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ²
- 1. 2. ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΊΠΈΠ½Π΅ΡΠΈΠΊΠΈ ΡΠ°ΡΡΠ²ΠΎΡΠ΅Π½ΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ²
- 1. 3. Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΠΎΠ΄Ρ ΠΎΠ΄Ρ ΠΊ ΠΎΡΠ΅Π½ΠΊΠ΅ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ² ΠΏΡΠΈ ΠΈΡ ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΈ
- ΠΠΠ‘ΠΠΠ ΠΠΠΠΠ’ΠΠΠ¬ΠΠΠ― Π§ΠΠ‘Π’Π¬ (Π‘ΠΠΠ‘Π’ΠΠΠΠΠ«Π ΠΠ‘Π‘ΠΠΠΠΠΠΠΠΠ―)
- ΠΠΠΠΠ 2. ΠΠΠ’ΠΠ ΠΠΠΠ« Π ΠΠΠ’ΠΠΠ«
- ΠΠΠΠΠ 3. ΠΠ‘ΠΠΠΠΠ«Π Π ΠΠΠ£ΠΠ¬Π’ΠΠ’Π« Π ΠΠ₯ ΠΠΠ‘Π£ΠΠΠΠΠΠ
- 3. 1. ΠΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΊΠΈΠ½Π΅ΡΠΈΠΊΠΈ ΡΠ°ΡΡΠ²ΠΎΡΠ΅Π½ΠΈΡ
3.2. ΠΡΠ΅Π½ΠΊΠ° Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΈΠ»ΠΈ Π½Π΅Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΎΡΠΊΠ°Π·Π° ΠΎΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π±ΠΈΠΎΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΠΈ Π΄Π»Ρ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π°ΠΌΠ»ΠΎΠ΄ΠΈΠΏΠΈΠ½Π°, ΠΈΠ±ΡΠΏΡΠΎΡΠ΅Π½Π° ΠΈ Π°ΡΠ΅Π½ΠΎΠ»ΠΎΠ»Π° ΠΈ Π·Π°ΠΌΠ΅Π½ΠΎΠΉ ΠΈΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΊΠΈΠ½Π΅ΡΠΈΠΊΠΈ ΡΠ°ΡΡΠ²ΠΎΡΠ΅Π½ΠΈΡ (ΠΏΡΠΎΡΠ΅Π΄ΡΡΠ° «Π±ΠΈΠΎΠ²Π΅ΠΉΠ²Π΅Ρ»).
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΡΠ·Π°ΠΌΠ°ΡΡΠ΅Π² Π.Π., ΠΠΎΡΠΎΡΠ΅Π΅Π² Π. Π. ΠΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΡ Π²ΠΎΡΠΏΡΠΎΠΈΠ·Π²Π΅Π΄Π΅Π½Π½ΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ²: ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π°ΡΠΏΠ΅ΠΊΡΡ // ΠΠ΅Π΄ΠΎΠΌΠΎΡΡΠΈ ΠΠ¦ΠΠ‘ΠΠ. Π., 2007. — № 1.
- Π. Π¨Π°Ρ . Π‘ΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ, Π±ΠΈΠΎΠ²Π΅ΠΉΠ²Π΅ΡΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΡΠΈΡΡΠ΅ΠΌΡ Π±ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ // WHO prequalification program. 2007.
- ΠΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½Π°Ρ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΏΠ΅Ρ Π‘Π‘Π‘Π . ΠΡΠΏ. 1. ΠΠ±ΡΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ Π°Π½Π°Π»ΠΈΠ·Π° / ΠΠ Π‘Π‘Π‘Π . 11-Π΅ ΠΈΠ·Π΄., Π΄ΠΎΠΏ. — Π.: ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 1987. — 336 Ρ.
- ΠΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΡΠΉ ΡΠ΅Π΅ΡΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ², «Π Π΅ΠΌΠ΅Π΄ΠΈΡΠΌ», Π., 2008 — Ρ.1,2.
- ΠΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΡΠΉ ΡΡΠ°Π½Π΄Π°ΡΡ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ². ΠΠ±ΡΠ°Ρ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΏΠ΅ΠΉΠ½Π°Ρ ΡΡΠ°ΡΡΡ «Π Π°ΡΡΠ²ΠΎΡΠ΅Π½ΠΈΠ΅» Π., 2004. — 20 Ρ.
- Π. ΠΡΠ΅ΡΡΠΌΠ°Π½, Π. ΠΠ΅ΠΊΠ΅Ρ. ΠΠΎΠ½ΠΎΠ³ΡΠ°ΡΠΈΠΈ ΠΏΠΎ Π±ΠΈΠΎΠ²Π΅ΠΉΠ²Π΅ΡΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΠΈΠΎ-ΡΠ°ΡΠΌΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ // WHO prequalification program. 2007.
- Π. ΠΡΠ΅ΡΡΠΌΠ°Π½. ΠΠ°ΡΠ΅ΠΌ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΠΈΡΡ Π°Π½Π°Π»ΠΈΠ· Π½Π° ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΡΡΡ // WHO prequalification program. 2007.
- Π.Π. Π’ΠΈΡΠΎΠ², Π. Π. ΠΠΎΡΠΎΡΠ΅Π΅Π², Π. Π. ΠΡΠ·Π°ΠΌΠ°ΡΡΠ΅Π². ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΡΡΠ° «ΡΠ°ΡΡΠ²ΠΎΡΠ΅Π½ΠΈΠ΅» Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ²-Π΄ΠΆΠ΅Π½Π΅ΡΠΈΠΊΠΎΠ² ΡΠΈΠΏΡΠΎΡΠ»ΠΎΠΊΡΠ°ΡΠΈΠ½Π° // ΠΠ΅ΡΡΠ½ΠΈΠΊ ΠΠΠ£, ΡΠ΅ΡΠΈΡ: Ρ ΠΈΠΌΠΈΡ, Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ, ΡΠ°ΡΠΌΠ°ΡΠΈΡ. 2004, — № 2. — Ρ. 270−275.
- ΠΠ½ΡΡΡΡΠΊΡΠΈΡ ΠΏΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΌΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΡΠ΅Π½ΠΎΠ»ΠΎΠ» (ΠΡΠ°Π½Π°ΡΠ°ΡΠΌ).
- ΠΠ½ΡΡΡΡΠΊΡΠΈΡ ΠΏΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΌΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΡΠ΅Π½ΠΎΠ»ΠΎΠ» (Π©Π΅Π»ΠΊΠΎΠ²ΡΠΊΠΈΠΉ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π½ΡΠΉ Π·Π°Π²ΠΎΠ΄).
- ΠΠ½ΡΡΡΡΠΊΡΠΈΡ ΠΏΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΌΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΡΠ΅Π½ΠΎΠ»ΠΎΠ»1. ΠΠΊΡΠΈΡ.
- ΠΠ½ΡΡΡΡΠΊΡΠΈΡ ΠΏΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΌΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΠ±ΡΠΏΡΠΎΡΠ΅Π½ (Π Π£Π ΠΠΎΡΠΈΡΠΎΠ²ΡΠΊΠΈΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΠΉ Π·Π°Π²ΠΎΠ΄).
- ΠΠ½ΡΡΡΡΠΊΡΠΈΡ ΠΏΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΌΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΠΠ-400.
- ΠΠ½ΡΡΡΡΠΊΡΠΈΡ ΠΏΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΌΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΠΎΡΠ²Π°ΡΠΊ®-.
- ΠΠ½ΡΡΡΡΠΊΡΠΈΡ ΠΏΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΌΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΠΌΠ΅Π»Π°ΡΠΊΠ°ΡΠ΄ΠΈΠΎ.
- Π. ΠΠΈΠ½Π΄Π΅Π½Π±Π΅Π³. ΠΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ ΡΠΏΠΈΡΠΊΠ° ΠΎΡΠ½ΠΎΠ²Π½ΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ² (EML) ΡΠΎΠ³Π»Π°ΡΠ½ΠΎ ΡΠΈΡΡΠ΅ΠΌΠ΅ Π±ΠΈΠΎΡΠ°ΡΠΌΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ (BCS) // WHO prequa-lification program. 2007.
- ΠΠ°Π»ΡΡΠ΅Π² Π. ΠΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΡΠ΅ ΡΠ΅Π³Π»Π°ΠΌΠ΅Π½ΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π±ΠΈΠΎΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ². www. pharma-center.kiev.ua/messages/O1 malcev bio. ppt
- IT. ΠΠΎΠ²ΠΈΠΊΠΎΠ²Π°. // Π€Π°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΠ΅ΡΡΠ½ΠΈΠΊ. Π., 2008. — № 4.
- Π. ΠΠ°ΡΠ»Π°. Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΡΠ΅Π³ΡΠ»ΡΡΠΎΡΠ½ΡΠ΅ ΡΡΠ΅Π±ΠΎΠ²Π°Π½ΠΈΡ ΠΊ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΠΌ ΠΈ ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ². Π., «Π€Π°ΡΠΌΡΠΎΠ΄ΡΡΠΆΠ΅ΡΡΠ²ΠΎ», 2007.
- ΠΡΠΈΠΊΠ°Π· ΠΠ Π£ΠΊΡΠ°ΠΈΠ½Ρ № 190 «ΠΠΎΡΡΠ΄ΠΎΠΊ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΡ ΠΈΡΠΏΡΡΠ°Π½ΠΈΠΉ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ² ΠΏΡΠΈ ΠΎΡΡΡΠ΅ΡΡΠ²Π»Π΅Π½ΠΈΠΈ ΡΠΊΡΠΏΠ΅ΡΡΠΈΠ·Ρ ΡΠ΅Π³ΠΈΡΡΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ²» / ΠΠ Π£ΠΊΡΠ°ΠΈΠ½Ρ. 2007.
- ΠΡΠ΅Π½ΠΊΠ° Π±ΠΈΠΎΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ². ΠΠ΅ΡΠΎΠ΄ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠΊΠ°Π·Π°Π½ΠΈΡ. ΠΠΎΠ΄ ΡΠ΅Π΄. Π. Π. ΠΡΠΊΠ΅ΡΠ°, Π. Π. Π€ΠΈΡΠ΅Π½ΠΊΠΎ. Π., 2004. — 34 Ρ.
- ΠΡΠ΅Π½ΠΊΠ° Π±ΠΈΠΎΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ ΡΡΠ΅Π΄ΡΡΠ². ΠΠ΅ΡΠΎΠ΄ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠΊΠ°Π·Π°Π½ΠΈΡ. ΠΠΎΠ΄ ΡΠ΅Π΄. Π. Π. ΠΡΠΊΠ΅ΡΠ°, Π. Π. Π€ΠΈΡΠ΅Π½ΠΊΠΎ. Π., 2008. — 34 Ρ.
- Π‘. ΠΠ»ΡΠΉΠ½. ΠΡΠΎΠ΅ΠΊΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈ ΠΊΠ°Π»ΠΈΠ±ΡΠΎΠ²ΠΊΠ° ΠΎΠ±ΠΎΡΡΠ΄ΠΎΠ²Π°Π½ΠΈΡ Π΄Π»Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ ΡΠ΅ΡΡΠΎΠ² ΡΠ°ΡΡΠ²ΠΎΡΠ΅Π½ΠΈΡ // WHO prequalification program. 2007.
- Π‘. Π‘ΡΠ°Π²ΡΠ°Π½ΡΠΊΠΈΠΉ Π‘ΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠΎΠ΅ΠΊΡ ΠΈ ΠΎΡΠ΅Π½ΠΊΠ° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π±ΠΈΠΎΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΠΈ. Π‘ΡΠ΅Π΄Π½ΡΡ Π±ΠΈΠΎΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΡ // WHO prequalification program. 2007.
- Π’. ΠΠ΅ΠΊΠΊΠ΅Ρ. Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΡΡΠ²ΠΎΡΠ΅Π½ΠΈΡ ΠΈ Π·Π°ΡΠ²ΠΊΠΈ // WHO prequalification program. 2007.
- Π’Π΅Π½ΡΠΎΠ²Π° Π.Π., ΠΠΆΠ³ΠΈΡ ΠΈΠ½ Π. Π‘. ΠΠ΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½Π°Ρ ΡΠΎΡΠΌΠ° ΠΈ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ². (ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π² Π±ΠΈΠΎΡΠ°ΡΠΌΠ°ΡΠΈΡ). Π.: ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 1974.-Π‘. 57−58.
- Π―. ΠΠ΅Π»ΠΈΠ½ΠΊ. ΠΡΠ±ΠΎΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Π΄Π»Ρ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π±ΠΈΠΎΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΠΈ // WHO prequalification program. 2007.
- Π―. ΠΠ΅Π»ΠΈΠ½ΠΊ. ΠΡΠ΅Π½ΠΊΠ° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΠΎ Π±ΠΈΠΎΡΠΊΠ²ΠΈΠ²Π°Π»Π΅Π½ΡΠ½ΠΎΡΡΠΈ (ΡΠ°ΡΠΌΠ°ΠΊΠΎ-ΠΊΠΈΠ½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ in vivo) // WHO prequalification program. 2007.
- A Manual for Drug Regulatory Authorities. Marketing Authorization of Pharmaceutical Products with Special Reference to Multisource (Generic) Products). -WHO, 1999.
- A. Hussain, L. Lesko, K. Lo et all. The Biophannaceutics Classification System: Highlights of the FDA’s Draft Guidance // Dissolution Technologies. 1999. -Vol. 6, № 2.
- A. Patel, B. Prajapati, R. Moria, C.Patel. In vitro evaluation of marketed antimalarial chloroquine phosphate tablets // J. Vect Borne Dis 42. 2005, — № 4 -pp. 147−150.
- A.G. Stosik, H.E. Junginger, S. ΠΠΎΡΡ. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metoclopramide Hydrochloride // Journal of Pharmaceutical Sciences. 2008. — Vol. 97. — pp. 3700−3708.
- B. Chuasuwan, V. Binjesoh, J.E. Polli. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Diclofenac Sodium and Diclofenac Potassium / Journal of Pharmaceutical Sciences. 2009. — Vol. 98. — pp. 1206−1219.
- Bolton, S. Con-elation in pharmaceutical statistics: practical and clinical applications, 2nd ed. Marcel Dekker Inc., New York, 1991. — pp. 211−245.
- British Pharmacopoeia. 2007.
- C. Becker, J. Dressman, G. Amidon et al, Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ethambutol Dihydrochloride // Journal of Pharmaceutical Sciences. -2008. Vol. 97. — pp. 1350−1360.
- Π‘. Becker, J.B. Dressman, G.L. Amidon. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Isoniazid // Journal of Pharmaceutical Sciences. 2007. — Vol. 96. — pp. 522−531.
- C. Becker, J. Dressman, G. Amidon et al, Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ethambutol Dihydrochloride // Journal of Pharmaceutical Sciences. -2008. Vol. 97. — pp. 1350−1360.
- C. Becker, J.B. Dressman, G.L. Amidon. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Pyrazinamide // Journal of Pharmaceutical Sciences. 2008. — Vol. 97. — pp. 3709−3720.
- C. Saccone, J. Tessore, S. OHvera, N. Meneces. Statistical Properties of the Dissolution Test of USP // Dissolution Technologies. 2004. — Vol. 11, № 3.
- D. Fortunato. Effects of Dissolution Method Development for Immediate Release Solid Oral Dosage Forms // Dissolution Technologies. 2005. — Vol. 12, № 1. Π j.
- D. Murphy, D. Holt. The Biopharmaceutics Classification System (BCS) does it have any relevance to the Analyst? // PASG Autumn Meeting. — 2006.
- Directive 2004/27/EC of the European Parliament and of the Council, Art. 10.1.-2004.
- Dressman Π J. and Reppas Π‘. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs I I Eur. J. Pharm. Sci. 2000. — Nol 1. — pp. 73−80.
- Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: Immediate Release dosage forms // Pharmaceutical Research. 1998. — Vol. 15, № 1.
- E. A. Gianotto, R. P. Arantes, M. J. Lara-Filho et all. Dissolution test for glibenclamide tablets // Quimica Nova. 2007. — Vol. 30, No. 5. — pp. 1218−1221.
- E. Jantratid, S. Prakongpan, J.B. Dressman et al. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cimetidine // Journal of Pharmaceutical Sciences. -2006. Vol. 95. — pp. 974−984.
- European Pharmacopoeia, 5th ed. 2005.
- EMEA, The rules governing medicinal products in the European Union Investigation of Bioavailability and Bioequivalence, v. 3C. -1998.
- FIP Guidelines for Dissolution Testing of Solid Oral Products // Dissolution Techno! 1997.-№ 4. — pp. 5−14.
- F1P/AAPS Guidelines to Dissolution/Ρ vitro Release Testing of Novel / Special Dosage Forms. AAPS PharmSciTech. 2003.
- G. Digenis, T. Gold, and V. Shah. Cross-linking of gelatin capsules and its relevance to their in vitro-in vivo performance // Journal of Pharmaceutical Sciences. 1994. — Vol. 83. -pp. 915−921.
- G.E. Granero, M.R. Longhi, C. Becker. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Acetazolamide // Journal of Pharmaceutical Sciences. -2008. Vol. 97. — pp. 3691−3699.
- G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability// Pharmaceutical Research. 1995. — Vol. 12, № 3.
- Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations /U.S. Department of
- Health and Human Services. Food and Drag Administration. Center for Drug Evaluation and Research (CDER). FDA, 2003.
- Guidance for Industry. Statistical Approaches to Establishing Bioequiva-lence / Food and Drug Administration. Center for Drug Evaluation and Research (CDER). -FDA, 2001.
- Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms / Food and Drug Administration. Center for Drug Evaluation and Research (CDER). -FDA, 1997.
- Guidance for industry: extended release oral dosage forms: development, evaluation and application of an in vitro! in vivo correlation / Food and Drug Administration. Center for Drug Evaluation and Research (CDER). FDA, 1997.
- Guidance on the Selection of Comparator Pharmaceutical Products for Equivalence Assessment of Interchangeable Multisource (Generic) Products / WHO Technical Report Series, № 902. WHO, 2002.
- Guidelines for the preparation of biowaiver monographs for J Pharm Sci & FIP Website.
- H. G. Ferraz, L. N. Carpentieri, S. P. Watanabe. Dissolution Profile Evaluation of Solid Pharmaceutical Forms Containing Chloramphenicol Marketed in
- Brazil // Brazilian Archives of Biology and Technology. 2007. — Vol.50, β. 1 -pp.57−65.
- H. Kortejarvi, M. Yliperttula, J.B. Dressman et al. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ranitidine Hydrochloride // Journal of Pharmaceutical Sciences. -2005. Vol. 94. pp. 1617−1625.
- IT. Lennerna 1998. Human intestinal permeability // Journal of Pharmaceutical Sciences. -1998. Vol. 87. — pp. 403−410.
- H. Pohhast, J. Dressman, H. Junginger et all. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ibuprofen // Journal of Pharmaceutical Sciences. 2005. — Vol. 94, № 10. — pp 2121−2131.
- H. Potthast. Biowaiver // WHO prequalification program. 2007.
- H. Rettig, J. Mysicka. IVIVC: Methods and Applications in Modified-Release Product Development // Dissolution Technologies. 2008. -Vol. 15, № 1.
- ICH Harmonised Tripartite Guideline: Organisation of The Common Technical Document for the Registration of Pharmaceuticals for Human Use. M4. -Geneva: ICH, 2004.
- ICH Harmonised Tripartite Guideline: The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality M4Q (Rl). -Geneva: ICH, 2002.
- ICH Harmonised Tripartite Guideline: The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Safety. M4S (R2). -Geneva: ICH, 2002.
- ICH Harmonised Tripartite Guideline: The Common Technical Documcnt for the Registration of Pharmaceuticals for Human Use: Efficacy. M4E (Rl). Geneva: ICH, 2002.
- International Pharmacopoeia, 4th ed. 2006.
- J. Arnal, I. Gonsalez-Alvarez, M. Bermejo. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Aciclovir // Journal of Pharmaceutical Sciences. -2008. Vol. 97. — pp. 5061−5073.
- J. Burmicz. Technical Note: Why Is Vibration an Issue for Dissolution Testing? // Dissolution Technologies. 2008. — Vol. 15, № 1.
- J. Cook, IT. Bockbrader. An Industrial Implementation of the Biophar-maceutics Classification System // Dissolution Technologies 2002. — Vol. 9, № 2.
- J. Emami. In vitro-in vivo correlation: From theory to applications // Journal of Pharmaceutical Sciences. 2006. — Vol. 9. — pp. 169−189.
- J. Hofer, V. Gray. Examination of Selection of Immediate Release Dissolution Acceptance Criteria // Dissolution Technologies. 2003. — Vol. 10, No 1.
- Japanese Pharmacopoeia, 14th ed. 2001.
- J-M. Cardot, E. Beyssac, M.Alric. In vitro-In vivo Correlation: Importance of Dissolution in IVIVC // Dissolution Technologies. 2007. — Vol. 14, No 1.
- K. Fliszar, R. Forsyth, Z. Li, G. Martin. Effects of Dissolved Gases in Surfactant Dissolution Media // Dissolution Technologies. 2005. — Vol. 12, No 3.
- K. Kiehm, J.Dressman. Evaluation of Drug Adsorption to Membrane Filters under Biowaiver Test Conditions // Dissolution Technologies. 2008. -Vol. 15, No 4.
- L. Kalantzi, C. Reppas, J. Dressman et all. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Acetaminophen (Paracetamol) // Journal of Pharmaceutical Sciences. — 2006. — Vol. 95. — pp. 4−14.
- L. Kalantzi, C. Reppas, J. Dressman et all. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Acetaminophen (Paracetamol) // Journal of Pharmaceutical Sciences. 2006. — Vol. 95. — pp. 4−14.
- L. Rago. Introduction to the course on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical Classification System // WHO prequalification program 2007.
- L. Rago. WHO Guidelines for Registration Requirements to Establish Interchangeability // WHO prequalification program 2007.
- L. Yu, G. Amidon, J. Polli. Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions // Pharmaceutical Research. 2002. -Vol. 19, β. 7.
- L. Zhang, Π. Ha, B. Kleintop et all. Differences in In vitro Dissolution Rates Using Single-Point and Multi-Point Sampling // Dissolution Technologies. -2007.-Vol. 14, № 4.
- M. Chen, V. Shah, R. Patnaik. Bioavailability and Bioequivalence: An FDA Regulatory Overview // Pharmaceutical Research. 2001. — Vol. 18, β. 12.
- M. Vogt, H. Derendorf, J. Kramer et al. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Prednisolone // Journal of Pharmaceutical Sciences. 2007. — Vol. 96. — pp. 27−37.
- M. Vogt, H. Derendorf, J. Kramer. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Prednisone // Journal of Pharmaceutical Sciences. 2007. — Vol. 96. — pp. 1480−1489.
- Marival Bermejo. Dissolution Methodologies and IVIVC // ODD Lake Tahoe. WHO, 2004.
- Moore, J.W. and Flanner, H.H. Mathematical comparison of dissolution profiles. Pharm. Tech. 2006. — Vol. 20, № 6. — pp. 64−74.
- Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability. — WHO Technical Report Series, № 937. WHO, 2006.
- Note for Guidance on the nvestigation of Biovailability and Bioequiva-lence / CPMP/EWP/QWP/l 401 /98. EMEA, 2001.
- Q. Wang, D. Ma, J. Higgins. Analytical Method Selection for Drug Product Dissolution Testing // Dissolution Technologies. 2006. — Vol. 14, № 6.
- R. Rolli. Automation of Dissolution Tests for Biowaiver Studies // Dissolution Technologies. 2002. — Vol. 9, № 3.
- R. Williams. Bioequivalence Harmonization and International Bio waivers. WHO, 2008.
- R. Williams. Confidentiality, Exclusivity, and Bioavailability and Bioequivalence in the Context of Pharmaceutical Data Protection and Registration of Medicines // International Seminar, Lima. WHO, 2004.
- R.H. Manzo, M.E. Olivera, G.L. Amidon et al. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Amitriptyline Hydrochloride // Journal of Pharmaceutical Sciences. 2006. — Vol. 95. — pp. 966−973.
- S. Grube, P. Langguth, H.E. Junginger. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Quinidine Sulfate // Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jps.21 606.
- S. Rani, A. Pargal. Bioequivalence: An overview of statistical concepts // Indian J Pharmacol. 2004. — Vol. 36, № 4. — pp. 209−216.
- The United States Pharmacopeia, 30th revision. 2007.
- V. Joshil, J. Blodgett, J. George, J. Brinker. Impact of Sample Preparation on Dissolution Testing: Drug Binding and Extractable Impurities and Their Effect on Dissolution Data // Dissolution Technologies. — 2008. Vol. 15, № 3.
- V. Pillay, R. Fassihi. Unconventional Dissolution Methodologies // Journal of Pharmaceutical Sciences. 1999. — Vol. 88. — pp. 931−940.
- V. Shah, Y. Tsong, P. Sathe, R. Williams. Dissolution Profile Comparison Using Similarity Factor, f2 / Food and Drug Administration. Center for Drug Evaluation and Research (CDER). FDA, 2004.
- V. Shah. Dissolution: A Quality Control Test vs. A Bioequivalence Test // Dissolution Technologies. 2001. — Vol. 8, № 4.
- W. Hauck, R. Manning, T. Cecil et all. Proposed Change to Acceptance Criteria for Dissolution Performance Verification Testing // Dissolution Technologies. 2007. — Vol. 14, № 3.
- WHO Model List of Essential Medicines 15-th ed. WHO, 2007.
- WHO Technical Report Series 937 / WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO, 2006.
- WHO Technical Report Series 943 / WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO, 2006.1. Z)1. ΠΠΠΠΠΠΠΠ ΠΠΠ‘Π’Π